Batavia Biosciences has entered a collaboration with RocketVax, a subsidiary of Swiss Rockets AG, for the development of vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the SARS-CoV-2 virus.    RocketVax is developing a promising second generation COVID-19 vaccine candidate, called RVX-13 which, instead of containing only one COVID-19 derived antigen, comprises...